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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S399were younger and had higher levels of hip-related pain and
disability. The LBP group also had a higher number of painful
spinal levels and pelvic pain provocation tests. Results should be
interpreted with caution due to the low sample size. Further
research is warranted to explore the cause and effect relationship
and underlying pain mechanisms associated with co-existing hip
OA and LBP.DSPCC 35 mg TID (n[ 98) DSPCC 35 mg BID (n[ 104) Placebo (n[ 103)
(n[ 96) (n[ 102) (n[ 96)
Subjects with  30% reduction from baseline to week 12 75 (78.1 %) 70 (68.6%) 58 (60.4%)
P value 0.0078 0.2271
Subjects with  50% reduction from baseline to week 12 60 (62.5%) 57 (55.9%) 44 (45.8%)
P value 0.0205 0.1575
P-values are compared with placebo.712
LOWER-DOSE DICLOFENAC CAPSULES DEVELOPED USING
SOLUMATRIX FINE PARTICLE TECHNOLOGY RESULT IN CLINICALLY
MEANINGFUL IMPROVEMENTS IN PAIN IN A PHASE 3 STUDY OF
PATIENTS WITH OSTEOARTHRITIS
C. Young y, D. Parenti y, M. Hochberg z. y Iroko Pharmaceuticals, LLC,
Philadelphia, PA, USA; zUniv. of Maryland, Baltimore, MD, USA
Purpose: Osteoarthritis (OA) is characterized by acute and chronic pain
and reduced physical function. Non-steroidal anti-inﬂammatory drugs
(NSAIDs) are frequently prescribed for the management of OA pain. As a
class, NSAIDs are associated with dose-related serious gastrointestinal,
cardiovascular, and renal adverse events which has prompted interna-
tional health authorities and the United States Food and Drug Admin-
istration to recommend that NSAIDs be used at the lowest effective dose
for the shortest possible duration. Diclofenac submicron particle con-
taining capsules (DSPCC) consisting of submicron drug particles and a
proprietary combination of excipients were developed using SoluMa-
trix Fine Particle Technology to provide efﬁcacy at lower doses than
commercially available diclofenac drug products and are licensed for
treatment of mild-to-moderate acute pain in adults. As previously
reported, DSPCC 35 mg three times daily (TID) signiﬁcantly reduced the
Western Ontario and McMaster University Osteoarthritis Index
(WOMAC) pain subscale score compared with placebo (P ¼ 0.0024) in a
phase 3 study in adults with OA pain of the hip or knee. Therewas some
evidence of improvement in theWOMAC pain subscale score compared
with placebo for DSPCC 35 mg twice daily (BID), although this did not
achieve statistical signiﬁcance (P ¼ 0.08). We report the results for
measures of clinically meaningful pain relief following treatment with
low-dose DSPCC in the phase 3 study.
Methods: This multicenter, randomized, double-blind, placebo-con-
trolled study enrolled patients 40 years with clinically and radio-
logically conﬁrmed (Kellgren-Lawrence grade II-III) hip or knee OA pain.
Eligible patients were chronic NSAID and/or acetaminophen users with
baseline WOMAC pain subscale scores 40 mm (based on 100-mm
Visual Analog Scale) and a documented OA ﬂare (15-mm increase in
WOMAC pain subscale score from screening). Patients were random-
ized to receive DSPCC 35 mg TID, DSPCC 35 mg BID, or placebo for 12
weeks. Efﬁcacy parameters included responder rates for patients who
achieved a reduction of 10 mm in pain intensity from baseline based
on theWOMAC pain subscale score at week 2, 6, and 12; the proportion
of patients with a reduction (0%-100%) in WOMAC pain subscale score
at week 12 (continuous responder analysis); and the proportion of
patients who discontinued from the study due to lack of efﬁcacy.
Results: Overall, 305 patients were randomized. The mean (SD) age of
patients was 61.6 (8.9) years and 66.6% were female. Both DSPCC 35 mg
TID (86/96, 89.6% [P ¼ 0.007]) and BID (86/102, 84.3% [P ¼ 0.0148])
resulted in signiﬁcantly more patients achieving 10-mm reductions in
the WOMAC pain subscale score from baseline compared with placebo
(67/96, 69.8%) at week 12. Similar effects were noted at week 2 (DSPCC
35 mg TID: 73/94, 77.7% [P ¼ 0.0130]; DSPCC 35 mg BID: 78/100, 78.0%
[P ¼ 0.0098]; placebo: 56/92, 60.9%) and week 6 (DSPCC 35 mg TID: 76/
86, 88.4% [P ¼ 0.0031]; DSPCC 35 mg BID: 76/91, 83.5% [P ¼ 0.0338];
placebo: 61/87, 70.1%). The DSPCC 35 mg TID and BID groups experi-
enced greater reductions in pain intensity compared with placebo.
More than two-thirds of patients in the DSPCC 35 mg TID and BIDgroups achieved a reduction of30% in theWOMAC pain subscale score
from baseline and amajority of patients achieved a reduction of50% at
week 12 based on continuous responder analysis (Table). No patients in
the DSPCC 35 mg TID group and 2 patients (1.9%) in the DSPCC 35 mg
BID group withdrew from the study due to lack of efﬁcacy compared
with 6 patients (5.8%) in the placebo group.Conclusions: Treatment with DSPCC 35 mg TID and BID resulted in
clinically meaningful improvements in pain in this study in patients
with OA of the hip or knee.
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INTRA-ARTICULAR INFILTRATION THERAPY FOR PATIENTS WITH
GLENOHUMERAL OSTEOARTHRITIS. A SYSTEMATIC REVIEW OF THE
LITERATURE.
S. Colen y, P. Geervliet z, D. Haverkamp x, M. van den Bekerom k. yUniv.
Hosp. Leuven, Leuven, Belgium; zGemini Hosp., Dept. of Orthopaedic
Surgery, Den Helder, Netherlands; x Slotervaart Hosp., Dept. of
Orthopaedic Surgery, Amsterdam, Netherlands; kOnze Lieve Vrouwe
Gasthuis, Dept. of Orthopaedic Surgery, Amsterdam, Netherlands
Purpose: Conservative treatments are especially in patients with GH-
OA important, since shoulder arthroplasty has its limitations. In this
systematic review we will evaluate the current evidence regarding the
efﬁcacy of intra-articular inﬁltration treatment options in patients with
glenohumeral osteoarthritis (GH-OA).
Methods: The following databases are searched: Pubmed/Medline,
Cochrane Clinical Trial Register, Embase and the WHO clinical trial
register. All intra-articular injection products used for the treatment of
shoulder OA in humans are included.
Results: A total of 8 studies could be included in this review. Hyaluronic
acid (HA) showed effect sizes of 2.07, 2.02 and 2.11 at 6,12 and 26weeks
follow-up, respectively. Placebo (1.60 , 1.82 and 1.68) also showed stable
effect sizes at the same time points. The efﬁcacy of corticosteroids (CS)
decreased rapidly at follow-up (1.08, 0.43 and 0.19). Although statistical
signiﬁcant, the maximum difference in effect sizes between HA and
placebo was only 0.43 with absolute values between 2.0 and 6.4 on a
100-point VAS for pain.
Conclusion: Intra-articular treatment with HA has a good efﬁcacy at
follow-up compared to baseline. However, the difference in efﬁcacy
between HA and placebo never reaches the minimal clinically impor-
tant difference at any of the follow-up points. We are not able to give
clear recommendations for the use of intra-articular CS injections in
patients with GH-OA. In future research we recommend to focus on
sufﬁciently powered randomized trials to compare the efﬁcacies of HA,
CS, placebo and other intra-articular treatment options in patients with
GH-OA.
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IMPROVEMENT IN CARTILAGE FOLLOWING INTRA-ARTICULAR
INJECTION OF TG-C, A CELL MEDIATED GENE THERAPY FOR
OSTEOARTHRITIS
B. Lee y, S. Totterman z, D. Gale z, A. Schreyer z, J. Cho y, T. Kim y,
Y. Park y, E. Jeong y. yKolon Life Sci., Inc., Gwacheon-si, Republic of Korea;
zQmetrics Tech., Rochester, NY, United States
Purpose: A randomized single-blind phase IIa trial was conducted in 28
patients with knee OA to determine both safety and efﬁcacy of TG-C.
TG-C is a cell mediated gene therapy that contains non-transduced
(hChonJ) and transduced (hChonJb#7) human allogeneic chondrocytes.
hChonJb#7 cells were transduced with TGF-b1 gene using retroviral
vector, while hChonJ cells were not modiﬁed. The hChonJb#7 cells were
